![](/img/cover-not-exists.png)
Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial
Dispenzieri, A, Jacobus, S, Vesole, D H, Callandar, N, Fonseca, R, Greipp, P RVolume:
24
Year:
2010
Language:
english
Pages:
6
DOI:
10.1038/leu.2010.129
File:
PDF, 327 KB
english, 2010